## Contents

1  Mechanism of Action and Pharmacokinetics of Biologics  .......... 1
   Alan C. Moss

2  Antitumor Necrosis Factor Agents in Ulcerative Colitis .......... 13
   Kindra Clark-Snustad, Ives Hot, and Scott Lee

3  Antitumor Necrosis Factor Agents in Crohn’s Disease .......... 33
   Byron P. Vaughn

4  Anti-TNF Therapy for Treatment of Extraintestinal Manifestations of Inflammatory Bowel Disease .......... 49
   David I. Fudman and Sarah N. Flier

5  Use of Biologics in the Postoperative Management of Crohn’s Disease ............................................ 59
   Benjamin H. Click and Miguel Regueiro

6  Biologics in Pregnancy and Breastfeeding  ......................... 81
   Jill K.J. Gaidos and Sunanda V. Kane

7  Concomitant Use of Immunosuppressive Therapy with Tumor Necrosis Factor (TNF) Antagonists in Inflammatory Bowel Disease ................................................................. 101
   Parambir S. Dulai and Corey A. Siegel

8  Therapeutic Drug Monitoring of Biologic Agents  .................. 113
   Frank I. Scott and Mark T. Osterman

9  Use of Biologics in Crohn’s Disease and Ulcerative Colitis Prior to Surgery and Perioperative Risks ................. 129
   Afrin Kamal and Bret Lashner

10 Cessation of Biologics: Can It Be Done?  .......................... 141
   Hang Hock Shim and Cynthia H. Seow
11  Biologic Therapy in Pediatric Inflammatory Bowel Disease ........ 163
   Sonal Patel and Jennifer Strople

12  Infectious Complications of Biologics ........................................ 185
   Renée M. Marchioni Beery and Joshua R. Korzenik

13  Tumor Necrosis Factor-Alpha Inhibitors and Risks of Malignancy ........ 213
   Julia T. Hughes and Millie D. Long

14  Noninfectious and Nonmalignant Complications of Anti-TNF Therapy .......... 231
   Uni Wong and Raymond K. Cross

15  Biosimilars in Inflammatory Bowel Disease 2017: State of the Science, State of the Art, and State of the Finances ........ 261
   Christina Y. Ha and Asher Kornbluth

16  Anti-integrin Agents in IBD: Efficacy and Risk of Complications .......... 283
   Jimmy K. Limdi and Francis A. Farraye

17  Novel Agents in Inflammatory Bowel Disease .......................... 303
   Fernando Velayos

18  Quality, Safety, and Practical Considerations of Using Biologic Therapies .......... 315
   Leilei Zhu and Gil Y. Melmed

Index ................................................................. 329
Treatment of Inflammatory Bowel Disease with Biologics
Cheifetz, A.S.; Feuerstein, J.D. (Eds.)
2018, XI, 335 p. 22 illus., 19 illus. in color., Hardcover
ISBN: 978-3-319-60275-2